One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Biocryst Pharmaceuticals now clears that threshold, with a jump from 72 to 85 Thursday.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
This unique rating identifies technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the market's biggest winners tend to have an RS Rating of over 80 in the early stages of their moves.
Looking For Winning Stocks? Try This Simple Routine
Biocryst Pharmaceuticals is not currently offering a proper buying opportunity. With earnings just released, let's see if the stock goes on to build a base that could launch a new move.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 0% to 30%. Revenue rose from 31% to 85%.
The company earns the No. 138 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab and Vertex Pharmaceuticals are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
